1174913-80-4

Basic information

• Product Name: (R)-2-Aminomethyl-4-boc-morpholine
• Synonyms: (R)-2-(Aminomethyl)morpholine-4-carboxylic acid tert-butyl ester;4-Morpholinecarboxylic acid, 2-(aMinoMethyl)-, 1,1-diMethylethyl ester, (2R)-;(R)-tert-butyl 2-aMinoMethylMorpholine-4-carboxylate;tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate;(R)-2-Aminomethyl-4-boc-morpholine;(R)-4-Boc-2-aminomethylmorpholine
• CAS NO: 1174913-80-4
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.2774
• Mol File: 1174913-80-4.mol

Chemical Properties

• Boiling Point: 311℃
• Flash Point: 142℃
• Appearance: /
• Density: 1.078
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.37±0.29(Predicted)
• CAS DataBase Reference: (R)-2-Aminomethyl-4-boc-morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Aminomethyl-4-boc-morpholine(1174913-80-4)
• EPA Substance Registry System: (R)-2-Aminomethyl-4-boc-morpholine(1174913-80-4)

Safety Data

• Hazardous Substances Data: 1174913-80-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(R)-2-Aminomethyl-4-boc-morpholine is used as an amino-protecting reagent for protecting amino groups from unwanted reactions in organic synthesis. Its use ensures that the amino groups remain intact and unreacted during the synthesis process, allowing for the selective formation of desired products.
Used in Pharmaceutical Production:
(R)-2-Aminomethyl-4-boc-morpholine is utilized in the production of pharmaceuticals, where it plays a crucial role in the synthesis of various drug molecules. Its ability to protect amino groups allows for the controlled formation of complex pharmaceutical compounds, contributing to the development of new and effective medications.
Used in Peptide and Nucleotide Derivative Preparation:
(R)-2-Aminomethyl-4-boc-morpholine is employed in the preparation of peptide and nucleotide derivatives, where the protection of amino groups is essential for the successful synthesis of these biologically relevant molecules. The use of (R)-2-Aminomethyl-4-boc-morpholine ensures the selective formation of desired peptide and nucleotide structures, facilitating advancements in the fields of biochemistry and molecular biology.
Used as an Intermediate in Organic Synthesis:
(R)-2-Aminomethyl-4-boc-morpholine also serves as an intermediate in organic synthesis, where it can be further modified or transformed into other useful compounds. Its versatility and protective properties make it a valuable component in the synthesis of a wide range of organic molecules, including those with potential applications in various industries.

InChI:InChI=1S/C10H20N2O3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7,11H2,1-3H3/t8-/m1/s1

Upstream product

• 1132683-15-8 tert-butyl (2S)-2-(azidomethyl)morpholine-4-carboxylate 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 606139-90-6 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}morpholine-4-carboxylate 
• 1308849-93-5 (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate 
• 148638-76-0 tert-butyl (2S)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 52520-62-4 (2S)-4-benzyl-2-<<(p-tolylsulfonyl)oxy>methyl>morpholine 

Downstream Products

• 1174913-72-4 tert-butyl (R)-2-((benzyloxycarbonylamino)methyl)morpholine-4-carboxylate 
• 1308849-94-6 (R)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-95-7 (R)-tert-butyl 2-((2-amino-4-methylphenylamino)methyl)morpholine-4-carboxylate 
• 1308849-96-8 (R)-4-(1-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-5-methyl-1H-benzo[d]imidazol-2-yl)-3,5-difluorobenzoic acid 
• 1308849-97-9 (R)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-lH-benzo[d]imidazol-l-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1400589-53-8 1,1-dimethylethyl (2R)-2-{[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl}-4-morpholinecarboxylate 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

COMBINATION THERAPIES FOR TREATING PAIN

This invention generally relates to a combination therapy comprising the use of a substituted benzoimidazole compound and a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, and, in particular, to the use of methyl 2-((2-(2,6-difluoro-4- (meth

BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H- benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates

Identification of inhibitors of checkpoint kinase 1 through template screening

Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. Using template screening, a fragment